Concepedia

Joel Martin

JM

22

Publications

3K

Citations

20

H-Index

1982

Active since

Affiliations

Regeneron (United States)(Current)

University of Southern California

Novo Nordisk (Denmark)

University of Illinois Urbana-Champaign

Joel Martin is an author at Regeneron (United States) specializing in medicine, signal transduction, and cell signaling.

Top concepts

MedicineCell BiologyCell SignalingSignal TransductionBiologyGeneticsImmunologyPharmacologyNatural SciencesMolecular Physiology

Publications per year

1982–2020

22

Publications

22

Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab

Nicholas Papadopoulos, Joel Martin, Qin Ruan et al. · Angiogenesis · 2012 · 1K citations · Full text

Inflammation, Binding Kinetics, Vegf Trap +11

Dual blockade of IL‐4 and IL‐13 with dupilumab, an IL‐4Rα antibody, is required to broadly inhibit type 2 inflammation

Audrey Le Floc’h, Jeanne Allinne, Kirsten Nagashima et al. · Allergy · 2019 · 448 citations · Full text

p493F12 kinase: A novel MAP kinase expressed in a subset of neurons in the human nervous system

Abdi A. Mohit, Joel Martin, Carol A. Miller · Neuron · 1995 · 206 citations

Signal Transduction, Molecular Neuroscience, Molecular Physiology +12

Development of Clinical-Stage Human Monoclonal Antibodies That Treat Advanced Ebola Virus Disease in Nonhuman Primates

Kristen E. Pascal, Drew Dudgeon, John C. Trefry et al. · The Journal of Infectious Diseases · 2018 · 178 citations · Full text

A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies

Dimitris Skokos, Janelle Waite, Lauric Haber et al. · Science Translational Medicine · 2020 · 141 citations

Rows per page

1–5 of 22